Phase 1 Relapsed Acute Myeloid Leukemia Clinical Trials
5 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–5 of 5 trials
Recruiting
Phase 1
Imetelstat Combinations in Relapsed AML
Relapsed Acute Myeloid Leukemia
Douglas Tremblay36 enrolled1 locationNCT07320235
Recruiting
Phase 1Phase 2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Acute Myeloid LeukemiaMixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia+10 more
University of Washington62 enrolled1 locationNCT04797767
Recruiting
Phase 1Phase 2
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Stanford University20 enrolled1 locationNCT06561152
Recruiting
Phase 1
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Acute Leukemia of Ambiguous LineageRefractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital24 enrolled10 locationsNCT06177067
Recruiting
Phase 1
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseRefractory Acute Myeloid Leukemia+1 more
Memorial Sloan Kettering Cancer Center15 enrolled7 locationsNCT06017258